Your browser is no longer supported. Please, upgrade your browser.
Settings
CCXI [NASD]
ChemoCentryx, Inc.
Index- P/E- EPS (ttm)-0.92 Insider Own0.70% Shs Outstand69.61M Perf Week2.41%
Market Cap1.05B Forward P/E- EPS next Y-1.85 Insider Trans-16.13% Shs Float53.19M Perf Month12.80%
Income-63.40M PEG- EPS next Q-0.55 Inst Own72.10% Short Float10.59% Perf Quarter-69.19%
Sales69.20M P/S15.20 EPS this Y13.60% Inst Trans-10.44% Short Ratio1.23 Perf Half Y-73.88%
Book/sh5.19 P/B2.87 EPS next Y8.20% ROA-12.10% Target Price- Perf Year-72.83%
Cash/sh5.32 P/C2.80 EPS next 5Y- ROE-16.10% 52W Range9.53 - 70.29 Perf YTD-75.95%
Dividend- P/FCF- EPS past 5Y4.80% ROI-13.50% 52W High-78.82% Beta1.45
Dividend %- Quick Ratio7.10 Sales past 5Y- Gross Margin- 52W Low56.24% ATR0.94
Employees133 Current Ratio7.10 Sales Q/Q73.30% Oper. Margin-90.00% RSI (14)48.92 Volatility5.00% 7.18%
OptionableYes Debt/Eq0.07 EPS Q/Q-20.60% Profit Margin-91.50% Rel Volume0.19 Prev Close14.89
ShortableYes LT Debt/Eq0.04 Earnings- Payout- Avg Volume4.57M Price14.89
Recom2.50 SMA20-3.11% SMA5012.18% SMA200-65.67% Volume0 Change0.00%
Jul-07-21Upgrade Stifel Hold → Buy $26 → $31
May-07-21Downgrade SVB Leerink Outperform → Mkt Perform
May-07-21Downgrade Stifel Buy → Hold $93 → $26
May-07-21Downgrade Raymond James Strong Buy → Outperform
May-07-21Downgrade Piper Sandler Overweight → Neutral $80 → $25
May-07-21Downgrade JP Morgan Neutral → Underweight $57 → $17
Mar-02-21Reiterated H.C. Wainwright Buy $83 → $101
Mar-02-21Initiated Stifel Buy $93
Oct-29-20Downgrade JP Morgan Overweight → Neutral $63 → $60
Jun-17-20Initiated BTIG Research Buy $70
May-27-20Initiated Wells Fargo Overweight $79
May-12-20Reiterated H.C. Wainwright Buy $60 → $69
Jan-24-20Reiterated H.C. Wainwright Buy $40 → $60
Nov-26-19Reiterated Piper Jaffray Overweight $17 → $54
Nov-26-19Reiterated H.C. Wainwright Buy $23 → $40
Mar-27-19Upgrade B. Riley FBR Neutral → Buy $12.50 → $22
Feb-11-19Initiated Piper Jaffray Overweight $20
Sep-07-18Initiated B. Riley FBR Neutral $12.50
Aug-14-18Downgrade JP Morgan Overweight → Neutral
Jun-28-18Initiated Raymond James Strong Buy
Aug-02-21 03:01PM  
08:30AM  
Jul-27-21 06:13AM  
Jul-21-21 04:24AM  
Jul-10-21 06:44AM  
Jul-09-21 04:31PM  
Jul-08-21 02:25AM  
Jul-07-21 11:14PM  
09:30AM  
08:21AM  
Jul-06-21 03:21PM  
02:35PM  
10:03AM  
10:00AM  
09:47AM  
09:17AM  
08:30AM  
08:30AM  
07:01AM  
05:40AM  
Jul-05-21 11:36PM  
11:09PM  
11:00PM  
10:35PM  
06:18PM  
04:30PM  
04:15PM  
11:38AM  
10:10AM  
09:58AM  
08:30AM  
05:40AM  
Jul-04-21 10:50PM  
12:19PM  
11:15AM  
10:30AM  
Jul-03-21 09:00PM  
03:13PM  
Jul-02-21 10:50PM  
10:50PM  
10:00PM  
04:10PM  
03:36PM  
02:50PM  
10:15AM  
10:00AM  
09:32AM  
08:33AM  
05:40AM  
Jul-01-21 10:00PM  
02:10PM  
01:40PM  
01:15PM  
12:25PM  
11:05AM  
10:35AM  
08:32AM  
05:40AM  
Jun-30-21 10:12PM  
06:46PM  
04:38PM  
03:10PM  
01:44PM  
12:10PM  
11:00AM  
09:00AM  
08:32AM  
05:27AM  
Jun-29-21 11:35PM  
11:33PM  
07:44PM  
06:15PM  
04:41PM  
03:00PM  
02:15PM  
02:10PM  
12:30PM  
10:00AM  
08:31AM  
05:19AM  
01:30AM  
Jun-28-21 10:50PM  
08:00PM  
05:43PM  
04:16PM  
03:05PM  
01:35PM  
01:00PM  
12:30PM  
12:29PM  
11:00AM  
10:05AM  
09:50AM  
08:30AM  
08:00AM  
05:40AM  
01:00AM  
Jun-27-21 10:30AM  
Jun-26-21 01:56PM  
01:34PM  
ChemoCentryx, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. It develops Avacopan, an orally administered selective complement 5a receptor inhibitor for the treatment of anti-neutrophil cytoplasmic autoantibody-associated vasculitis; and completed Phase II clinical trial for the treatment of patients with severe hidradenitis suppurativa, as well as patients with complement 3 glomerulopathy. The company is also developing CCX559, an orally-administered inhibitor for programmed death protein 1/programmed death-ligand 1 for the treatment of various cancers; and CCX507, an orally-administered inhibitor of the chemokine receptor CC9, which has completed Phase I clinical trial or the treatment of inflammatory bowel disease. In addition, it develops CCX587 for the treatment of TH17 driven diseases. ChemoCentryx, Inc. was incorporated in 1996 and is headquartered in Mountain View, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Tyree James LDirectorMay 21Option Exercise0.004,660017,729May 24 08:19 PM
Parker Geoffrey M.DirectorMay 21Option Exercise0.004,660013,350May 24 08:09 PM
Jain RitaDirectorMay 21Option Exercise0.004,660022,886May 24 07:55 PM
Tyree James LDirectorMay 21Sale9.762,45423,95615,275May 24 08:19 PM
Butt TausifEVP, Chief Operating OfficerMay 07Buy11.0610,870120,24110,870May 10 07:48 PM
Jain RitaDirectorMar 27Option Exercise0.005,251018,226Mar 30 08:45 PM
Parker Geoffrey M.DirectorMar 05Sale56.3830,0001,691,46812,690Mar 08 08:28 PM
Parker Geoffrey M.DirectorMar 04Sale60.201,910114,98042,690Mar 08 08:28 PM
Edwards Thomas A.DirectorMar 02Sale70.061,10077,063119,857Mar 03 08:33 PM
Kwan Pui SanPrincipal Acctg OfficerMar 01Option Exercise10.463,34735,0126,579Mar 01 08:54 PM
Cappel Markus J.Chief Bus. Officer & TreasurerMar 01Option Exercise10.2433,092338,972118,918Mar 03 08:39 PM
Cappel Markus J.Chief Bus. Officer & TreasurerMar 01Sale68.4333,0922,264,44385,826Mar 03 08:39 PM
Kwan Pui SanPrincipal Acctg OfficerMar 01Sale68.523,347229,3353,232Mar 01 08:54 PM
Cappel Markus J.Chief Bus. Officer & TreasurerFeb 09Option Exercise11.027007,71486,526Feb 11 08:02 PM
Cappel Markus J.Chief Bus. Officer & TreasurerFeb 09Sale69.6670048,76585,826Feb 11 08:02 PM
Edwards Thomas A.DirectorFeb 09Sale70.0340028,014120,957Feb 11 07:52 PM
Cappel Markus J.Chief Bus. Officer & TreasurerFeb 08Option Exercise11.027,42081,76893,246Feb 08 08:31 PM
Cappel Markus J.Chief Bus. Officer & TreasurerFeb 08Sale67.307,420499,35185,826Feb 08 08:31 PM
Cappel Markus J.Chief Bus. Officer & TreasurerFeb 05Option Exercise11.028058,87186,631Feb 08 08:31 PM
Cappel Markus J.Chief Bus. Officer & TreasurerFeb 05Sale67.0780553,99485,826Feb 08 08:31 PM
Cappel Markus J.Chief Bus. Officer & TreasurerFeb 04Option Exercise11.021,40015,42887,226Feb 08 08:31 PM
Kwan Pui SanPrincipal Acctg OfficerFeb 04Option Exercise10.463,34735,0126,579Feb 08 08:25 PM
Cappel Markus J.Chief Bus. Officer & TreasurerFeb 04Sale67.141,40093,99585,826Feb 08 08:31 PM
Kwan Pui SanPrincipal Acctg OfficerFeb 04Sale65.003,347217,5553,232Feb 08 08:25 PM
Edwards Thomas A.DirectorFeb 02Sale60.9420,0001,218,844121,357Feb 04 07:58 PM
Kwan Pui SanPrincipal Acctg OfficerJan 25Option Exercise9.704,18440,5647,416Jan 27 07:25 PM
Cappel Markus J.Chief Bus. Officer & TreasurerJan 25Option Exercise11.021,37515,15287,201Jan 27 08:22 PM
Cappel Markus J.Chief Bus. Officer & TreasurerJan 25Sale67.031,37592,17285,826Jan 27 08:22 PM
Kwan Pui SanPrincipal Acctg OfficerJan 25Sale65.004,184271,9603,232Jan 27 07:25 PM
Schall Thomas J.President and CEOJan 01Option Exercise0.0087,89902,356,456Jan 07 08:40 PM
KANAYA SUSAN MEVP, CFO and Sec.Jan 01Option Exercise0.0030,3330135,263Jan 07 08:32 PM
Cappel Markus J.Chief Bus. Officer & TreasurerJan 01Option Exercise0.0021,100097,347Jan 07 08:26 PM
Edwards Thomas A.DirectorDec 28Sale61.5010,782663,093141,357Dec 29 06:58 PM
Edwards Thomas A.DirectorDec 24Sale61.1814,218869,904152,139Dec 29 06:58 PM
Kwan Pui SanPrincipal Acctg OfficerDec 15Option Exercise10.0742,593428,94345,825Dec 16 07:46 PM
Schall Thomas J.President and CEODec 15Option Exercise14.3117,619252,1282,286,176Dec 16 07:51 PM
Schall Thomas J.President and CEODec 15Sale65.0117,6191,145,4502,268,557Dec 16 07:51 PM
Kwan Pui SanPrincipal Acctg OfficerDec 15Sale65.0642,5932,771,2373,232Dec 16 07:46 PM
Schall Thomas J.President and CEODec 14Option Exercise14.3111,153159,5992,279,710Dec 16 07:51 PM
Kwan Pui SanPrincipal Acctg OfficerDec 14Option Exercise7.058,95763,15812,189Dec 16 07:46 PM
Schall Thomas J.President and CEODec 14Sale65.0311,153725,2462,268,557Dec 16 07:51 PM
Kwan Pui SanPrincipal Acctg OfficerDec 14Sale65.028,957582,3983,232Dec 16 07:46 PM